ReviewAmerican journal of cancer research2026
BRAF mutation and tumor immune microenvironment in new era.
Review in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Activation of the BRAF kinase is implicated in the oncogenesis of multiple human tumors, particularly thyroid cancer, colorectal cancer and melanoma. BRAF mutations serve as pivotal modulators of the immunomodulatory landscape within tumors, critically shaping host immune responses and modulating efficacy to cancer immunotherapy. Here, we reviewed the impact of BRAF mutations on the composition and function of tumor immune microenvironment and summarized current therapeutic strategies targeting BRAF. Overall, BRAF mutations significantly modulates cancer treatment outcomes through its effects on immune regulation. Targeting BRAF mutations at different stages of tumor initiation and progression may provide valuable insights for the development of innovative clinical interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.